Provided by Tiger Fintech (Singapore) Pte. Ltd.

Centessa Pharmaceuticals plc

24.76
+0.60502.51%
Volume:303.99K
Turnover:7.57M
Market Cap:3.32B
PE:-13.84
High:25.30
Open:24.52
Low:24.43
Close:24.15
52wk High:25.30
52wk Low:9.60
Shares:134.07M
Float Shares:84.95M
Volume Ratio:1.99
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7885
EPS(LYR):-2.0595
ROE:-72.92%
ROA:-28.96%
PB:9.62
PE(LYR):-12.02

Loading ...

Truist Financial Sticks to Their Buy Rating for Centessa Pharmaceuticals (CNTA)

TIPRANKS
·
Oct 23

Centessa Pharmaceuticals Price Target Maintained With a $28.00/Share by Guggenheim

Dow Jones
·
Oct 06

Centessa Pharmaceuticals Plc : Jefferies Raises Target Price to $30 From $27

THOMSON REUTERS
·
Oct 06

Wells Fargo Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)

TIPRANKS
·
Oct 01

Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Disposal of Common Shares

Reuters
·
Sep 25

Tia L. Bush, Chief Technology & Quality Officer, Reports Disposal of Centessa Pharmaceuticals plc Common Shares

Reuters
·
Sep 12

Iqbal J. Hussain, General Counsel, Reports Disposal of Common Shares of Centessa Pharmaceuticals plc

Reuters
·
Sep 12

Mario Alberto Accardi, President of Orexin Program, Reports Disposal of Common Shares of Centessa Pharmaceuticals plc

Reuters
·
Sep 12

Centessa Pharmaceuticals Initiated at Overweight by Wells Fargo

Dow Jones
·
Sep 03

Wells Fargo Initiates Centessa Pharmaceuticals at Overweight With $31 Price Target

MT Newswires Live
·
Sep 03

Centessa Pharmaceuticals Plc : Wells Fargo Initiates Coverage With Overweight Rating; Price Target $31

THOMSON REUTERS
·
Sep 03

Centessa Pharmaceuticals Plc : Oppenheimer Resumes Coverage With Outperform Rating; Price Target $40

THOMSON REUTERS
·
Aug 29

European Equities Traded in the US as American Depositary Receipts Decline Thursday

MT Newswires Live
·
Aug 21

Iqbal J. Hussain, General Counsel, Reports Disposal of Centessa Pharmaceuticals plc Common Shares

Reuters
·
Aug 16

Centessa Pharmaceuticals PLC reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 12

Centessa Pharmaceuticals Q2 EPS $(0.38) Misses $(0.34) Estimate

Benzinga
·
Aug 12

Centessa Pharmaceuticals Reports Q2 2025 Results: Net Loss Widens to $50.3M, Increased R&D Spending Highlights Focus on Orexin Agonist Pipeline

Reuters
·
Aug 12

Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q2 Net Loss $0.38 a Share, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
Aug 12

Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025

Reuters
·
Aug 12

Centessa Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 31